MediGene starts Phase II trial with Etomoxir

MediGene (NMarkt: MDG) began a dose-escalating, 360-patient Phase II trial of Etomoxir, a carnitine-palmitoyl-transferase-1 ( CPT1) inhibitor, to treat congestive heart failure (CHF). ...